Among the case population, 52.1% of breast cancer patients had tumors with diameter ≥ 2cm, 54.2% of patients belonged to stage I/II, 42.7% of patients were ER positive, 48.5% were PR positive, and 67.5% were her-2 positive. This evidence concerns the gene ESR1 and breast carcinoma.